Rilexine 600 mg Tablets for Dogs

Country: Велика Британија

Језик: Енглески

Извор: VMD (Veterinary Medicines Directorate)

Активни састојак:

Cefalexin

Доступно од:

Virbac

АТЦ код:

QJ01DB01

INN (Међународно име):

Cefalexin

Фармацеутски облик:

Tablet

Тип рецептора:

POM-V - Prescription Only Medicine – Veterinarian

Терапеутска група:

Dogs

Терапеутска област:

Antimicrobial

Статус ауторизације:

Authorized

Датум одобрења:

2005-10-24

Карактеристике производа

Revised: May 2022
AN: 01398/2021
Page 1 of 5
SUMMARY OF THE PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Rilexine 600 mg Tablets for dogs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains:
- Active substance
Cephalexin………………………………………………….600
mg
(as Cefalexin Monohydrate)
For the full list of excipients see section 6.1.
3. PHARMACEUTICAL FORM
Tablets.
Creamy oblong tablet with small brown spots marked with a score line.
The tablets can be divided into halves.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bacterial skin infections in dogs (including deep
and superficial
pyodermas) caused by organisms susceptible to cefalexin.
For the treatment of urinary-tract infections in dogs (including
nephritis and cystitis) caused
by organisms susceptible to cefalexin.
4.3 CONTRA-INDICATIONS
Do
not
use
in
animals
which
are
known
to
be
hypersensitive
to
penicillins
and
cephalosporins.
Do not use in rabbits, guinea pigs, hamsters and gerbils.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As with other antibiotics which are excreted mainly by the kidneys,
unnecessary
accumulation may occur in the body when renal function is impaired. In
case of known
Revised: May 2022
AN: 01398/2021
Page 2 of 5
renal insufficiency, the dose should be reduced and antimicrobials
known to be
nephrotoxic should not be administered concurrently.
This product should not be used to treat puppies of less than 1 kg of
bodyweight.
Use of the product deviating from the instructions given in the SPC
may increase the
prevalence of bacteria resistant to the cefalexin and may decrease the
effectiveness of
treatment with other cephalosporins and penicillins, due to the
potential for cross-
resistance.
Use of the product should be based on susceptibility testing of the
bacteria isolated from
the animal. If this is not possible, therapy